Different approaches to valuing the lost productivity of patients with migraine

PharmacoEconomics

Volumn 19, Issue 9, 2001, Pages 917-925

  Lofland, Jennifer H ^a   Locklear, Julie C ^b   Frick, Kevin D ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ABSENTEEISM; ARTICLE; CLINICAL TRIAL; EMPLOYEE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; OFFICE WORKER; PATIENT SATISFACTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE;

ABSENTEEISM; COST OF ILLNESS; HUMANS; MIGRAINE DISORDERS; OCCUPATIONS; PATIENT SATISFACTION; PENNSYLVANIA; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0034797604     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119090-00003     Document Type: Article

References (34)

1. Burden of migraine in the United States: Disability and economic costs
2. Health care resource and lost labour costs of migraine headache in the US
3. Age-and sex-specific incidence rates of migraine with and without visual aura
4. Prevalence of migraine headache in the Unites States: Relation to age, income, race, and other sociodemographic factors
5. Impact of migraine in the United States: Data from the National Health Interview Survey
6. A multinational investigation of the impact of subcutaneous sumatriptan III: Workplace productivity and non-workplace activity
7. Changes in resource use and outcomes for migraine patients treated with sumatriptan: A managed care perspective
8. Subcutaneous sumatriptan for the treatment of migraine: Humanistic, economic, and clinical consequences
9. Lost workdays and decreased work effectiveness associated with headache in the workplace
10. Workplace productivity: A review of the impact of migraine and its treatment
11. Effectiveness of sumatriptan in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial
12. The economic burden of migraine to society
13. The willingness to pay for health changes, the human capital cost approach and the external costs
14. A practical guide for calculating indirect costs of disease
15. Indirect costs in economic studies: Confronting the confusion
16. Societal perspective on the burden of migraine in The Netherlands
17. Philosophical origins of the economic valuation of life
18. The friction cost method for measuring indirect costs of disease
19. How to calculate indirect costs in economic evaluations
20. The economic cost of migraine: Present state of knowledge
21. Controversies in measuring and valuing indirect costs of productivity foregone in a cost of illness evaluation
22. How to calculate indirect costs in economic evaluations
23. Towards a new approach for estimating indirect costs of disease
24. Estimating the cost of lost productivity in dyspepsia
25. How to calculate indirect costs in economic evaluations
26. Cost effectiveness and cost benefit of sumatriptan for patients with migraine
27. The impact of indirect costs on outcomes of health care programs
28. Cost benefit of sumatriptan to an employer
29. Psychological functioning of children who have recurrent migraine
30. Anxiety and depression in migraine